Is OBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OBI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OBI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OBI?
Key metric: As OBI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for OBI. This is calculated by dividing OBI's market cap by their current
revenue.
What is OBI's PS Ratio?
PS Ratio
23.7x
Sales
CA$1.63m
Market Cap
CA$38.74m
OBI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: OBI is expensive based on its Price-To-Sales Ratio (23.7x) compared to the UK Medical Equipment industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is OBI's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
OBI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
23.7x
Fair PS Ratio
13.9x
Price-To-Sales vs Fair Ratio: OBI is expensive based on its Price-To-Sales Ratio (23.7x) compared to the estimated Fair Price-To-Sales Ratio (13.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst OBI forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
UK£0.077
UK£0.60
+674.2%
8.3%
UK£0.65
UK£0.55
n/a
2
Dec ’25
UK£0.077
UK£0.60
+674.2%
8.3%
UK£0.65
UK£0.55
n/a
2
Nov ’25
UK£0.087
UK£0.57
+557.1%
13.0%
UK£0.65
UK£0.50
n/a
2
Oct ’25
UK£0.068
UK£0.55
+714.8%
18.2%
UK£0.65
UK£0.45
n/a
2
Sep ’25
UK£0.07
UK£0.55
+685.7%
18.2%
UK£0.65
UK£0.45
n/a
2
Aug ’25
UK£0.083
UK£0.55
+566.7%
18.2%
UK£0.65
UK£0.45
n/a
2
Jul ’25
UK£0.077
UK£0.55
+609.7%
18.2%
UK£0.65
UK£0.45
n/a
2
Jun ’25
UK£0.07
UK£0.55
+685.7%
18.2%
UK£0.65
UK£0.45
n/a
2
May ’25
UK£0.051
UK£0.55
+973.2%
18.2%
UK£0.65
UK£0.45
n/a
2
Apr ’25
UK£0.092
UK£0.57
+521.6%
13.0%
UK£0.65
UK£0.50
n/a
2
Jan ’25
UK£0.087
UK£0.57
+557.1%
13.0%
UK£0.65
UK£0.50
n/a
2
Dec ’24
UK£0.088
UK£0.57
+549.7%
13.0%
UK£0.65
UK£0.50
UK£0.077
2
Nov ’24
UK£0.12
UK£0.57
+400.0%
13.0%
UK£0.65
UK£0.50
UK£0.087
2
Oct ’24
UK£0.092
UK£0.57
+521.6%
13.0%
UK£0.65
UK£0.50
UK£0.068
2
Sep ’24
UK£0.095
UK£0.57
+505.3%
13.0%
UK£0.65
UK£0.50
UK£0.07
2
Aug ’24
UK£0.16
UK£0.57
+259.4%
13.0%
UK£0.65
UK£0.50
UK£0.083
2
Jul ’24
UK£0.13
UK£0.57
+360.0%
13.0%
UK£0.65
UK£0.50
UK£0.077
2
Jun ’24
UK£0.15
UK£0.57
+271.0%
13.0%
UK£0.65
UK£0.50
UK£0.07
2
May ’24
UK£0.19
UK£0.63
+228.9%
4.0%
UK£0.65
UK£0.60
UK£0.051
2
Apr ’24
UK£0.16
UK£0.63
+296.8%
4.0%
UK£0.65
UK£0.60
UK£0.092
2
Mar ’24
UK£0.17
UK£0.95
+458.8%
48.4%
UK£1.60
UK£0.60
UK£0.098
3
Feb ’24
UK£0.20
UK£0.95
+375.0%
48.4%
UK£1.60
UK£0.60
UK£0.10
3
Jan ’24
UK£0.20
UK£0.95
+363.4%
48.4%
UK£1.60
UK£0.60
UK£0.087
3
Dec ’23
UK£0.24
UK£0.95
+287.8%
48.4%
UK£1.60
UK£0.60
UK£0.088
3
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.